Role of EPAC1 Signalosomes in Cell Fate: Friends or Foes?

Karina Formoso, Frank Lezoualc’h * and Jeanne Mialet-Perez

INSERM UMR-1048, Institute of Metabolic and Cardiovascular Diseases, and Université de Toulouse III-Paul Sabatier, 31432 Toulouse, France; karina.formoso@inserm.fr (K.F.); Jeanne.perez@inserm.fr (J.M.-P.)

* Correspondence: Frank.Lezoualch@inserm.fr; Tel.: +33-561-325-646

Received: 29 July 2020; Accepted: 22 August 2020; Published: 25 August 2020

Abstract: The compartmentation of signaling processes is accomplished by the assembly of protein complexes called signalosomes. These signaling platforms colocalize enzymes, substrates, and anchoring proteins into specific subcellular compartments. Exchange protein directly activated by cAMP 1 (EPAC1) is an effector of the second messenger, 3′,5′-cyclic adenosine monophosphate (cAMP) that is associated with multiple roles in several pathologies including cardiac diseases. Both EPAC1 intracellular localization and molecular partners are key players in the regulation of cell fate, which may have important therapeutic potential. In this review, we summarize the recent findings on EPAC1 structure, regulation, and pharmacology. We describe the importance of EPAC1 subcellular distribution in its biological action, paying special attention to its nuclear localization and mechanism of action leading to cardiomyocyte hypertrophy. In addition, we discuss the role of mitochondrial EPAC1 in the regulation of cell death. Depending on the cell type and stress condition, we present evidence that supports either a protective or detrimental role of EPAC1 activation.

Keywords: EPAC1; cAMP; signalosomes; hypertrophy; cell death

1. Introduction

3′,5′-Cyclic adenosine monophosphate (cAMP) is a universal second messenger that regulates a wide spectrum of signaling pathways in cells [1,2]. In mammals, cAMP is synthesized from ATP by a family of enzymes named adenylate cyclases (ACs). The AC family is composed of 9 membrane-bound members (AC1–9) that are activated by G protein-coupled receptors (GPCRs) linked to stimulatory G proteins (Gs). The tenth member of the family is the soluble isoform AC10, more commonly known as sAC [3]. The activation of different signaling pathways in one cell by cAMP is not a casual but a rather complex and controlled mechanism that involves specific machinery. Indeed, compartmentation of cAMP involves various proteins including the cAMP-degrading enzymes, phosphodiesterases (PDEs), and scaffolding proteins such as A-kinase anchoring proteins (AKAPs) that sequester cAMP signalosome into specific places within the cell [3]. In addition, the functional effect of cAMP is achieved by different effectors that act alone or in concert with other proteins. Among them, the protein kinase A (PKA) is the one that has been described first and the one more thoroughly studied [4]. However, other cAMP effectors have been identified including the exchange proteins directly activated by cAMP (EPACs) [5–7].

The two EPAC isoforms, EPAC1 and EPAC2, are guanine nucleotide exchange factors (GEFs) that activate the Ras-like small GTPases, Rap1, and Rap2. EPAC1 is ubiquitously expressed and its potential involvement in central and peripheral diseases has been largely studied in recent years. For instance, EPAC1 has been linked to Alzheimer’s disease, depression, and retinal neurodegeneration [8,9]. EPAC1 is also involved in migration, proliferation, and apoptosis in several types of cancers [9–12]. The role of EPAC1 in cardiac pathologies such as heart failure and arrhythmias has been characterized using...
EPAC1 transgenic mouse models, although it remains a matter of discussion [13,14]. Consistent with cAMP compartmentation, EPAC1 is spatially and temporally regulated by scaffolding proteins and its effectors interconnect with other signaling pathways. Due to its multidomain structure, EPAC1 expresses within different subcellular compartments such as the nucleus, the cytosol, the mitochondria, and plasma membranes and its localization may vary depending on the cell type and the cell cycle phase [15]. Unravelling the mechanisms underlying EPAC1 subcellular distribution and its functional relevance in distinct pathologies will have an important impact on determining EPAC1’s potential role in therapy. After a brief description of the gene and the protein structure of EPAC1, this review will summarize the latest pharmacological tools developed to modulate EPAC1 activity. In addition, we will detail recent findings on EPAC1 compartmentation paying special attention to the functions exerted by the protein at the nuclei and mitochondria and their beneficial or detrimental effects on cell destiny. Given the presence of extensive bibliography in the field, we will emphasize the importance of these processes in the context of cardiac pathophysiology.

2. Gene, Expression, and Structure

EPAC1 is encoded by the Rap guanine nucleotide exchange factor 3 (RAPGEF3) gene that possesses three and four validated isoforms in humans (www.ncbi.nlm.nih.gov/gene/10411) and mice (www.ncbi.nlm.nih.gov/gene/223864), respectively. The Rap guanine nucleotide exchange factor 4 (RAPGEF4) gene codes for five EPAC2 validated isoforms in mice (https://www.ncbi.nlm.nih.gov/gene/56508) and eighteen EPAC2 variants in humans (https://www.ncbi.nlm.nih.gov/gene/11069). RAPGEF3 and RAPGEF4 genes are located in different chromosomes but share high sequence homology and functional similarities. Their difference lies mostly in their pattern of expression. In this sense, EPAC1 expression is rather ubiquitous and is found with high expression levels in the heart and kidney. Instead, EPAC2 expression is much more restricted being mainly expressed in the central nervous system and endocrine tissues including the pancreas [5,6,9]. Though the regulation of EPAC1 expression has not been fully described, work from Lai and collaborators [16] showed that binding of hypoxia-inducible factor 1α (HIF-1α) to the hypoxia-responsive element of the EPAC1 promoter might induce its transcription in mouse primary cortical cultures subjected to hypoxia. In addition, recent studies found that both mRNA and protein expression of EPAC1 are dependent on the TEAD transcription factor and the H3K27 acetylation (Histone 3 lysine 2) of the promoter of EPAC1. Upon cAMP-elevating stimuli, the inhibition of YAP/TAZ TEAD and HDAC1/3-mediated H3K27 deacetylation leads to decreased EPAC1 expression in cardiac fibroblasts. These results suggest that there might be a negative feedback loop on EPAC1 expression upon cAMP generation [17].

EPAC1 is a monomeric protein of approximately 100 KDa that contains a regulatory region and a catalytic region (Figure 1A,B). The regulatory region located in the N-terminal part of EPAC1 is composed of an N-terminal domain (NTD), the disheveled-Egl10-pleckstrin (DEP) domain, which ensures EPAC1 localization at the plasma membrane and a cyclic nucleotide-binding domain (CNB-B) that regulates EPAC1 GEF activity [18]. Both PKA and EPAC1 have a CNBD domain. It was initially proposed that the concentration of cAMP required to activate EPACs was 10 fold higher than to activate PKA [19]. However, further in vitro studies on the PKA in the holoenzyme complex and EPAC1 showed similar affinities for cAMP binding [20]. Of note, EPAC2 harbors a second CNB domain (named CNB-A) which binds cAMP with low affinity. CNB-A is not required for EPAC2 activation by cAMP but is involved in its subcellular localization [21]. The C-terminal part of the EPAC1 protein contains the catalytic region and possesses 3 defined domains, namely the Ras association domain (RA), the RAS exchange motif (REM), that is involved in the stabilization of the active conformation of EPAC1 and a cell division and cycle 25 homology domain (CDC25-HD). The latter is responsible for the guanine nucleotide exchange for Rap GTPases, Rap1, and Rap2 and possesses a nuclear targeting signal whose importance will be discussed below [9,22].
Figure 1. EPAC1 structure and activation. (A) Descriptive graph of EPAC1 domains. NTD, N-terminal domains (orange); Regulatory domain (green): DEP, disheveled-Egl10-pleckstrin domain; CNB-B, cyclic nucleotide-binding domain B; catalytic domain (purple): RA, RAS association domain; REM, RAS exchange motif; CDC25-HD, cell division & cycle 25 homology domain. (B) I-TASSER generated three-dimensional model of EPAC1 viewed from two different angles [23,24] (C) The conformational states of EPAC1 upon activation are depicted as follows: EPAC1closed state (inactive), EPAC1extended state (inactive), and EPAC1open state (active). (D) EPAC1 sequences corresponding to the mitochondrial and nuclear localization signals.

Most of the structural analyses on EPAC1 derive from EPAC2, given that purified recombinant EPAC1 protein is resistant to crystallographic study. The X-ray crystal structure studies have revealed that EPAC exists in two conformational states: In its inactive form (apo-EPAC), the regulatory region blocks the catalytic domain thereby, inhibiting the interaction of EPAC with its effector, Rap. Binding of cAMP induces a conformational change that allows the CDC25-HD catalytic region to interact with its Rap effector [25,26]. More recently, White and colleagues [27] using Small-Angle...
X-ray Scattering (SAXS) have shown that EPAC1 exists in three conformational states, two of which are in equilibrium in the absence of cAMP (EPAC1-closed and EPAC1-extended). In the extended conformation, the conformation of CNB is similar to a cAMP-bound like conformation but without the cAMP-binding pocket covered by a lid. Upon cAMP binding to the intermediate (EPAC1 extended) state, the regulatory NTD/DEP/CNB domain is locked away from the catalytic domains (Figure 1C) [27].

3. EPAC1 Pharmacological Modulators

Given the role of EPAC1 in disease development, there is a growing interest in identifying selective pharmacological molecules to modulate its activity. Several compounds specifically targeting EPAC1 have been described in recent reviews so we will describe briefly the last advances in the area [14,28]. The EPAC1 agonists are classified into nucleotide-like activators and non-cyclic-nucleotide activators. The cAMP analog, 8-CPT (8-(4-chloro-phenylthio)-2′-O-methyladenosine-3′,5′-cAMP) was the first EPAC1 agonist identified and it has been largely used to uncover EPAC1 biological action in cultured cells [19]. The 8-CPT compound preferentially activates EPAC1 over EPAC2 and is 30 to 100 times less potent than cAMP to activate PKA [19,29,30] but as 8-CPT displays a poor membrane permeability, an acetoxyethyl ester derivative named 8-CPT-AM was developed [31]. This chemical modification significantly improved the efficiency of the mother molecule, 8-CPT [31]. However, 8-CPT and 8-CPT-AM, as well as other 8-CPT derivatives, have been reported to induce off-targets such as PDE activation, thus requiring caution when analyzing their effects. Recently, Yarwood’s group identified, in a high throughput screening (HTS) study, the first known non-cyclic nucleotide (NCN) EPAC1 agonist, I942 with in vitro application [32,33]. NMR spectrometry analysis demonstrated that I942 can stabilize an inhibition-incompetent activation intermediate state of EPAC1 distinct from both active and inactive states [34]. Additionally, in a study carried out by the Zhou’s group, a series of non-cyclic nucleotide activators named 25g, 25q, 25n, 25u, 25e, and 25f with good selectivity over PKA were identified. Among them, compounds 25e, 25f, 25n, and 25u show a higher selectivity over EPAC1. Specifically, the agonist 25u inhibits STAT3 activation, and subsequent pro-inflammatory IL-6 signaling to Vascular cell adhesion protein 1 (VCAM1) induction, showing a higher activity than its precursor I942 [35]. Another non-cyclic nucleotide, SY009 agonist was isolated by ultra HTS in a library of 350,000 compounds. SY009 is chemically distinct from I942 and displays higher selectivity for EPAC1 over EPAC2 and PKA [36]. Subsequent studies must be performed to investigate the functional effects of these compounds.

Many studies reported detrimental effects of EPAC1 activation during stress conditions [9,14]. Therefore, efforts have been made to identify potential EPAC1 inhibitory compounds. Pioneer studies characterized small molecules that prevented both cAMP-dependent EPAC1 and EPAC2 activation. Among these pan-EPAC inhibitors, ESI-08 and ESI-09 were identified from HTS as non-cyclic compounds that impede EPAC’s activity [37–39]. Interestingly, ESI-09 has demonstrated significant pharmacological effect in preventing the invasion and metastasis of pancreatic and breast cancers, as well as protecting from fatal rickettsioses bacterial infection [39,40]. Nonetheless, thermal shift assays showed that high concentrations (>25 µM) of ESI-09 had a detrimental effect on protein stability [41]. Optimization of ESI-09 led to different inhibitors from which NY0123 showed to be a more potent inhibitor than its precursor in vitro [42]. The above-mentioned compounds are classified as competitive inhibitors of EPAC1, but non-competitive and uncompetitive inhibitors have also been characterized [14]. In the last two categories, both types of compounds bind to an allosteric site of the protein. While a non-competitive inhibitor binds both to the protein in the absence or presence of the substrate, an uncompetitive inhibitor requires that the protein substrate complex is previously formed. Of note, uncompetitive inhibitors are more effective at increasing concentrations of substrate, which highlights their potential for therapeutics. Compound 5376753, for example, is a non-competitive EPAC1 and EPAC2 inhibitor that was found by a combination of computational analyses and a Bioluminescence Resonance Energy Transfer (BRET)-based assay called CAMYEL and inhibits Rap1 activation [43]. The highly selective and potent EPAC1 uncompetitive inhibitor, CE3F4
was identified in an HTS assay in 2012 [29]. CE3F4 blocks EPAC1 guanine nucleotide exchange activity toward its effector Rap1 both in cell-free systems and in intact cells [29,44]. CE3F4 has been successfully used in a multitude of studies to reveal EPAC1-dependent biological action in different cell types [14]. The selectivity of (R)-enantiomer of CE3F4(CE3F4R) for EPAC1 is determined by one amino acid of difference with EPAC2 (EPAC1: Q270; EPAC2: K405) [45]. The binding site for the CE3F4R is located in the CNB domain of EPAC1, at a specific position that is exposed when cAMP binds, thus forming an EPAC1-cAMP-CE3F4 ternary complex. CE3F4R interacts with EPAC1 in an intermediate state that stabilizes its closed topology, thus preventing EPAC1 catalytic activity [45,46]. More recently, Laudette and collaborators [47] isolated a thieno [2.3-b]pyridine derivative (called AM-001) that behaves as a non-competitive and selective EPAC1 inhibitor with no effect on EPAC2 or PKA activity. Interestingly, AM-001 displays in vivo applications and mitigates cardiac hypertrophy, inflammation, and fibrosis after chronic β-adrenergic activation in mice. In addition, acute injection of AM-001 is cardioprotective against myocardial ischemia/reperfusion (I/R) injury [48]. Recently, Buffano and collaborators used cosolvent molecular dynamics to determine the binding site of AM-001 [49]. They found that the allosteric site of AM-001 lied in a pocket formed by CDC25-HD and CNB domains of EPAC1. Binding of AM-001 to this pocket stabilized an inactive “like” state of EPAC1 by strengthening the interaction of these two domains [49].

4. EPAC Compartmentation

4.1. Integration of Membrane Signaling

GPCRs function as a link between extracellular signals and intracellular signaling routes and play a crucial role in the activation of EPAC1. In the heart, β-adrenergic (β-AR) receptors are among the most important GPCRs that enhance myocardial performance in response to stress or exercise. β-ARs are activated by catecholamines (adrenaline, noradrenaline) and exist as three subtypes in the heart, from which subtypes β1- and β2- ARs activate Gs proteins (stimulatory G proteins), leading to cAMP formation while β2 also signals through Gi/o (inhibitory G proteins) [50,51]. Although cardiac β3-AR has not been described in detail yet, it is coupled to Gi/o proteins and NOS-dependent production of cGMP [52]. Acute stimulation of β-ARs is beneficial for the heart, nevertheless, prolonged activation may cause cardiac remodeling including hypertrophy and fibrosis, which can evolve into heart failure [53]. Interestingly, EPAC1 is activated by both β1-AR and β2-AR that induce different biological responses; pro- and anti-hypertrophy, respectively [54]. Of note, EPAC1 is increased at the onset of cardiac hypertrophy in a PKA-independent manner and EPAC1 pharmacological or genetic inhibition protects mice against cardiac hypertrophy and fibrosis during chronic β-AR stimulation [48,55,56].

Mechanistically (Figure 2), EPAC1 forms a molecular complex with the scaffold protein β-arrestin2 (β-ar2), when β1-AR is activated the complex is translocated to the plasma membrane. β-ar2 binds to the C-terminal part of the β1-AR allowing the activation of EPAC1 and subsequent cardiomyocyte hypertrophy [54,57]. Accordingly, β-ar2 knock-down prevented cardiomyocyte hypertrophy after activation of β1-AR with isoproterenol. It is important to highlight that the interaction of EPAC1 with β-ar2 depends also on the presence of the cAMP-specific PDE variant, PDE4D5. The latter interacts with β-ar2 hence inhibiting EPAC1 interaction necessary for its pro-hypertrophic effect [54]. Pro-hypertrophic signaling pathways of EPAC1 have been studied in depth [13]. The calcium-sensitive proteins, calcineurin, and calmodulin-dependent protein kinase II (CaMKII) act as key effectors of EPAC1 in its functional effect in cardiomyocytes [56,58–61]. Additional effectors have been shown to participate in this process. For instance, Morel and collaborators [62] showed that the pro-hypertrophic effect of EPAC1 involved the small GTPase, Rac. Moreover, EPAC1 has been shown to activate Rap2B-phospholipase C (PLC) and H-Ras leading to CaMKII activation [54] and it was shown that the activation of Ras through EPAC1 was dependent on PLC and IP3R [59,63].
The transcription factor, NFAT (Nuclear Factor of Activated T Cells) is a downstream effector of calcineurin, and mediates cardiac hypertrophy development. Upon its dephosphorylation by calcineurin, NFAT translocates to the nucleus to regulate its target genes [64]. Work from our laboratory shows that EPAC1 upregulates the expression of MCIPI, a well-known modulator of calcineurin signaling that possesses a series of NFAT response element in its promoter [62]. Besides, activation of EPAC1 leads to the upregulation and activation of Transient Receptor Potential Canonical (TRPCs) channels that sustain Ca$^{2+}$ influx and calcineurin/NFAT activity [65]. Yet, the silencing of EPAC1 suppressed the translocation of NFATc3/c4 induced by Isoproterenol in guinea pig hearts [66]. Aside from NFAT, EPAC1 effects on gene transcription involve other players like myocyte enhancer factor 2 (MEF2), a transcription factor involved in hypertrophy development [67]. In this sense, CaMKII activation by EPAC1 regulates histone deacetylases 4 and 5 (HDAC) by inducing their export from the nucleus thus derepressing MEF2 and leading to pro-hypertrophic signaling [59,63]. Interestingly, recent work from our laboratory shows that EPAC1 interacts with the G protein-coupled receptor kinase 5 (GRK5) to promote cardiac myocyte hypertrophy. Indeed, GRK5 acts as a downstream mediator of...
EPAC1, allowing the phosphorylation of HDAC5 and subsequent MEF2 activation following activation of β-AR with isoproterenol [48].

It is worth mentioning that EPAC1-calcineurin/CaMKII signaling pathway is not limited to the heart and mediates various biological actions such as neuronal death (see below). In diabetic nephropathy, increased EPAC1 mRNA levels lead to cell cycle arrest and cellular hypertrophy leading to kidney tubular hypertrophy [68]. Additionally, EPAC1 is also an important mediator of osteoclasts maturation induced by cAMP in bone-marrow cells. Silencing of EPAC1 in vitro reduced RANKL-mediated NFATc1 expression and osteoclasts differentiation [69].

4.2. EPAC Presence and Functional Relevance on the Nucleus

The presence of EPAC1 at the perinuclear envelope has been observed in many different cell types, suggesting an important role in the regulation of nuclear function. Anchoring of EPAC1 at the cytosolic side of the nuclear pore complex (NPC) has been reported to be responsible for EPAC’s nuclear localization. By a two-hybrid screen, Gloetrich and collaborators [70] showed that EPAC1 interacted with a component of the NPC, RanBP2, through its zinc finger domain. This interaction was sufficient for its localization to the nuclear membrane (NM) but inhibited Rap1-dependent EPAC activity. In another study, mass spectrometry analyses identified additional proteins complexed to EPAC1 at the NM, such as Ran, importin β1, and nucleoporins 98 and 205 [71]. However, in contrast with the previous study, the association of EPAC1 with Ran was demonstrated to be essential for its localization to the NM. Disruption of this complex avoids the nuclear localization of EPAC1, favoring its accumulation in the plasma membrane where EPAC1 inhibits neurite outgrowth [72].

Little is known to date about the exact function exerted by nuclear EPAC1, but growing evidence supports a role in the modulation of hypertrophy. Accordingly, Dogde-Kafka found that muscle-specific mAKAP assembled a cAMP-responsive network at the NM of cardiomyocytes with PDE4, PKA, and EPAC1 that finely tuned ERK5 activity through Rap1 to modulate hypertrophic response [74]. As an alternative mechanism, it was previously described that PLCε was an important downstream effector of cAMP/EPAC1 pathway through the action of Rap2B [75]. Zhang and collaborators [76,77] later demonstrated that PLCε was located at the NM of cardiomyocytes and formed a complex with AKAPβ and EPAC1 required for agonist-dependent hypertrophy. They elegantly showed that upon hypertrophic stimuli, PLCε downstream of EPAC1 generated diacylglycerol (DAG) from a PI4P pool in the perinuclear Golgi allowing activation of nuclear protein kinase D (PKD) and the release of nuclear Ca^{2+} necessary for HDAC5 nuclear export and stimulation of hypertrophic genes [77].

Besides hypertrophy, nuclear EPAC1 has been shown to regulate other cellular responses such as an epithelial-to-mesenchymal transition in lung carcinoma cells [78]. It is suggested that EPAC1 interacts with β-catenin, a protein that translocates to the nucleus upon prostaglandin E2 treatment and activates the transcription of a battery of genes involved in survival and metastasis. Interestingly, both
EPAC1/β-catenin interaction and PGE2-mediated transcription were abolished with the EPAC1 mutant deleted for the NPLS sequence (amino acids 764 to 838), indicating a preferential role of EPAC1 at the nuclear membrane. In Hela cells, Houston and collaborators [79] showed that EPAC1 was capable of mediating DNA-dependent protein kinase (DNA-PK) translocation from nucleus to the cytosol, proposing a new role for EPAC1 in the regulation of DNA repair process and Akt kinase activation. While this mechanism has not been observed in other cells or tissues, future studies will be necessary to assess its relevance in pathophysiological conditions.

4.3. EPAC Presence and Functional Relevance in the Mitochondria

Cytosolic cAMP is unable to cross the inner mitochondrial membrane and therefore local production of cAMP in mitochondria is carried out by the sAC which is activated in response to HCO3- and Ca2+ [3]. Mitochondrial localization of EPAC1 was determined jointly with its nuclear localization by Cheng’s laboratory in COS-7 cells [15]. After this, Wang and collaborators [80] found that EPAC1 and EPAC2 were present in isolated cardiac mitochondria. At the same time, our laboratory employing subfractioning of mitochondria found that EPAC1 was present in the mitochondrial inner membrane and matrix [81]. The presence of EPAC1 at the mitochondria was confirmed by subcellular fractionation together with live-cell co-localization imaging in vascular smooth muscle cells (VSMC) [82]. A putative mitochondrial localization signal was proposed by Qiao in the N-terminal region of EPAC1 [15]. Our laboratory narrowed down this putative sequence to a smaller sequence (del2-37, Figure 1D) and showed that it was responsible for the targeting of EPAC1 to the mitochondria [81].

Mitochondria play a crucial role in cell death by regulating necrosis and apoptosis. Recent advances in the field suggest that these processes are not independent of one another but are linked both functionally and mechanistically [83]. Briefly, apoptosis involves the permeabilization of the outer membrane (MOMP) and this process is regulated by the B cell lymphoma-2 (BCL-2) family of proteins. Namely, BCL-2, BCL-2-associated X protein (BAX), BCL-2 antagonist/killer 1 (BAK), BCL-2-like 11 (BIM), BH3 interacting domain death agonist (BID), the p53-upregulated modulator of apoptosis (PUMA), BCL-2-associated agonist of cell death (BAD), among others. Activation of BAX and BAK following MOMPC allows the exit of Cytochrome C into the cytosol to form the apoptosome. In this way activation of Caspase-9, -3, and -7 leads to apoptosis. Necrosis pathways, on the other hand, can be fired by calcium overload, increased cellular reactive oxygen species (ROS), and adenine nucleotide depletion. All these processes ultimately lead to the opening of the mitochondrial permeability transition pore (MPTP) in the inner mitochondrial membrane (IMM). This generates the dissipation of the proton gradient in the membrane (depolarization) and cell death.

EPAC1’s role in cell death has been reported in different models with opposite implications. In the heart, glucagon-like peptide receptor (GLP-1R) activation attenuated oxidative stress in cardiomyocytes treated with H2O2 in an EPAC1-dependent manner through the upregulation of antioxidant enzymes. Furthermore, the authors showed that, upon GLP-1R activation, a synergistic effect of EPAC1 and PKA protected the cells from apoptosis by impeding caspase-3 activity and upregulating Bcl-2 expression [84]. Accordingly, the work of Khaliulin and collaborators [85] found that activation of PKA and EPAC1 mediated the protection against I/R injury in rat hearts. It is noteworthy that simultaneous activations of EPAC1 and PKA were necessary to drive cardioprotection in the aforementioned studies. In addition, the precise localization of EPAC1 mediating these effects was not mentioned. In contrast, Wang and collaborators [80] showed that activation of sAC by HCO3-, which is specifically expressed in mitochondria, delayed transmembrane potential (ΔΨm) loss, Ca2+ entry, and MPTP opening. This effect was inhibited by the selective EPAC1 inhibitor CE3F4 [80]. Recent work from Jayarajan and collaborators [86] showed that sAC through EPAC1 controlled basal AMPK activity and thus supported mitochondrial clearance, cellular energy, and redox homeostasis in H9C2 cardiomyoblasts. In the kidney, activation of EPAC in proximal tubular epithelial cells showed a protective effect against cisplatin nephrotoxicity. The reduced apoptosis and the preservation of the cell-cell junction were dependent on EPAC and Rap activation [87].
The work reviewed so far favors the idea of a protective role for EPAC1, but work from our laboratory found that EPAC1 played a crucial role in inducing cell death in the heart. We found that EPAC1 KO mice subjected to myocardial I/R were protected from oxidative stress and cardiomyocyte apoptosis [48,81]. Consistently, genetic ablation of EPAC1 limited the upregulation of Bax and cytochrome C, the downregulation of Bcl2, and the activation of caspases 3 and 9. In a model of in vitro hypoxia-reoxygenation, activation of EPAC1 through sAC increased mitochondrial Ca$^{2+}$ uptake and ROS production leading to MPTP opening and cell death [81]. Particularly, Fazal and collaborators generated a mutant that lacked the mitochondrial signal (EPAC1 Δ2-37) and was excluded from the mitochondria. This mutant did not impair Rap1 activation, meaning that the EPAC1 cytosolic function was intact. Upon hypoxia and reoxygenation, cardiomyocytes transfected with this mutant exhibited less cell death than the controls, thus confirming a crucial role of mitochondrial EPAC1 in cell death. The contradicting results to that of Wang can be explained by the different models used to induce cardiomyocyte apoptosis in distinct pathophysiological contexts. In line with our results, EPAC1 inhibitors (ESI-09 and CE3F4) limited the accumulation of Ca$^{2+}$ in the mitochondria in the adrenocortical cell line (H295R) [88]. The Ca$^{2+}$ accumulation induced by overexpression of a mitochondrial-targeted sAC was inhibited [88].

After aortic banding in WT and EPAC1 KO mice, the absence of EPAC led to reduced apoptosis measured as TUNEL positive cells and reduced BAX expression in comparison with WT mice [89]. A role for EPAC1 in modulating mitochondrial dynamics was proposed since its genetic ablation or pharmacological inhibition impeded mitochondrial fission [82].

In the nervous system, recent work from Liu’s laboratory found that EPAC1 deletion protected against retinal neuronal apoptosis and necroptosis after retinal I/R injury [8]. In line with a neuroprotective effect of EPAC1 inhibition, Suzuki and colleagues found that stimulation of EPAC1 in cortical neurons increased apoptosis, Bax/BCL-2 ratio, and Bim/Bcl-2 interactions [90]. In addition, in vivo injection of an irreversible inhibitor of mitochondria complex II, 3-nitropropionic acid failed to promote neuronal apoptosis in EPAC1 KO mice [90]. These results suggest that EPAC1 induces neuron-specific apoptosis through increasing Bim expression.

In cancer also contradicting results have been shown in line with what we presented so far. In breast cancer cell lines, treatment with a pan-EPAC antagonist, ESI-09 prevents cell migration and induces apoptosis [91]. In contrast, the PDE4 inhibitor Rolipam aids A172 human glioblastoma cell line death through the activation of EPAC1 [92]. In lung cancer cells cAMP through EPAC action inhibits the repair of γ-ray-induced DNA damage by the degradation of X-ray repair cross-complementing protein 1 (XRCC1) [93]. However, these inconsistencies may be because different types of cancer cells can present different expression patterns and thus similar stimuli can have opposite outcomes.

5. Discussion

Although there are some conflicting results in the literature, EPAC1 has a proven effect on transcriptional regulation that plays an important role in cardiomyocyte hypertrophy. On the other side, in the mitochondria, EPAC1 would be crucial in the processes of cell death, both apoptosis, and necrosis, though further studies need to be carried out to understand the detailed mechanism. The information gathered in this review puts EPAC1 on a preferential place as a potential therapeutic target in cancer development, cardiovascular diseases, and neurodegenerative disorders, among others. In addition, although it is well known that age predisposes to the development of the aforementioned pathologies, very few studies have evaluated the potential role of EPAC1 in the process of aging itself. In line with this, the functions of EPAC1 identified in the different signalosomes are among the key factors that regulate aging. Namely, mitochondrial EPAC1 has been shown to regulate ROS, mitochondrial fission/fusion, and death pathways while nuclear EPAC1 modulates the localization of DNA repair enzymes. These results highlight the importance of studying the role of EPAC1 in aging. In the future, improved knowledge of the mechanisms of action of EPAC1 signalosomes will help to design original therapeutic tools for the treatment of various disorders.
Author Contributions: Writing—original draft preparation, K.F., J.M.-P. and F.L.; writing—review and editing, K.F., J.M.-P. and F.L.; supervision, J.M.-P. and F.L.; project administration, J.M.-P. and F.L.; funding acquisition, J.M.-P. and F.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from Institut National de la Santé et de la Recherche Médicale, Agence Nationale de la Recherche (ANR-17-CE14-0014-01, ANR-19-CE14-0038-01), Fondation pour la Recherche Médicale (Programme “Equipes FRM 2016”, DEQ20160334892 to F.L.), Fondation de France (00066331/00096289), Fédération Française de Cardiologie and Cardia Team project (IMI).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Chao, Y.C.; Surdo, N.C.; Pantano, S.; Zaccolo, M. Imaging cAMP nanodomains in the heart. Biochem. Soc. Trans. 2019, 47, 1383–1392. [CrossRef] [PubMed]
2. Sassone-Corsi, P. The Cyclic AMP Pathway. Cold Spring Harb. Perspect. Biol. 2012, 1–3. [CrossRef] [PubMed]
3. Pozdniakova, S.; Ladilov, Y. Functional Significance of the Adcy10-Dependent Intracellular cAMP Compartments. J. Cardiovasc. Dev. Dis. 2018, 5, 29. [CrossRef] [PubMed]
4. Torres-Quesada, O.; Mayrhofer, J.E.; Stefan, E. The many faces of compartmentalized PKA signalosomes. Cell Signal. 2017, 37, 1–11. [CrossRef] [PubMed]
5. Kawasaki, H.; Springett, G.M.; Mochizuki, N.; Toki, S.; Nakaya, M.; Matsuda, M.; Housman, D.E.; Graybiel, A.M. A family of cAMP-binding proteins that directly activate Rap1. Science 1998, 282, 2275–2279. [CrossRef] [PubMed]
6. De Rooij, J.; Zwartkruis, F.J.T.; Verheijen, M.H.G.; Cool, R.H.; Nijman, S.M.B.; Wittinghofer, A.; Bos, J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396, 474–477. [CrossRef]
7. Schleicher, K.; Zaccolo, M. Defining a cellular map of cAMP nanodomains. Mol. Pharmacol. 2020. [CrossRef]
8. Liu, W.; Ha, Y.; Xia, F.; Zhu, S.; Li, Y.; Shi, S.; Mei, F.C.; Merkley, K.; Vizzeri, G.; Motamedi, M.; et al. Neuronal Epac1 mediates retinal neurodegeneration in mouse models of ocular hypertension. J. Exp. Med. 2020, 1–19. [CrossRef]
9. Robichaux, W.G.; Cheng, X.X. Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development. Physiol. Rev. 2018, 98, 919–1053. [CrossRef]
10. Kumar, N.; Prasad, P.; Jash, E.; Saini, M.; Husain, A.; Goldman, A.; Sehrawat, S. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. Mol. Cell. Biochem. 2017, 1–12. [CrossRef]
11. Wang, X.; Luo, C.; Cheng, X.; Lu, M. Lithium and an EPAC-specific inhibitor ESI-09 synergistically suppress pancreatic cancer cell proliferation and survival. Acta Biochim. Biophys. Sin. 2017, 573–580. [CrossRef] [PubMed]
12. Xiong, G.-F.; Xu, R. Function of cancer cell-derived extracellular matrix in tumor progression. J. Cancer Metastasis Treat. 2016, 357–364. [CrossRef]
13. LezoualchF, H.; Fazal, L.; Laudette, M.; Conte, C.; Lezoualch, F.; Lezoualch, H.; Fazal, L.; Laudette, M.; Conte, C. Cyclic AMP sensor EPAC proteins and their role in cardiovascular function and disease. Circ. Res. 2016, 118, 881–897. [CrossRef]
14. Bouvet, M.; Blondeau, J.; Lezoualch, F. The Epac1 Protein: Pharmacological Modulators, Cardiac Signalosome Pathophysiology. Cells 2019, 8, 1543. [CrossRef] [PubMed]
15. Qiao, J.; Mei, F.C.; Popov, V.L.; Vergara, L.A.; Cheng, X. Cell Cycle-dependent Subcellular Localization of Exchange Factor Directly Activated by cAMP*. J. Biol. Chem. 2002, 277, 26581–26586. [CrossRef] [PubMed]
16. Lai, T.W.; Lin, S.-Z.; Lee, H.-T.; Fan, J.-R.; Hsu, Y.-H.; Wang, H.-J.; Yu, Y.-L.; Shyu, W.-C. HIF-1α binding to the Epac1 promoter recruits hematopoietic stem cells to the ischemic brain following stroke. J. Mol. Cell Biol. 2012, 4, 184–187. [CrossRef]
17. Ebrahimighaei, R.; McNeill, M.; Smith, S.A.; Wray, J.P.; Ford, K.L.; Newby, A.C.; Bond, M. Elevated cyclic AMP represses expression of exchange protein activated by cAMP (EPAC1) by inhibiting YAP-TED activity and HDAC-mediated histone deacetylation. BBA Mol. Cell Res. 2019, 1866, 1634–1649. [CrossRef]
18. Ponsioen, B.; Gloerich, M.; Rutsma, L.; Rehmann, H.; Bos, J.L.; Jalink, K. Direct Spatial Control of Epac1 by Cyclic AMP. Mol. Cell. Biol. 2009, 29, 2521–2531. [CrossRef]
19. Enserink, J.M.; Christensen, A.E.; de Rooij, J.; van Triest, M.; Schwede, F.; Genieser, H.G.; Dæskeland, S.O.; Blank, J.L.; Bos, J.L. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat. Cell Biol. 2002, 4, 1–6. [CrossRef]

20. Dao, K.K.; Teigen, K.; Kopperud, R.; Hodneland, E.; Schwede, F.; Christensen, A.E.; Martinez, A.; Dæskeland, S.O. Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. J. Biol. Chem. 2006, 281, 21500–21511. [CrossRef]

21. Niimura, M.; Miki, T.; Shibasaki, T.; Fujimoto, W.; Iwanaga, T.; Seino, S. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. J. Cell. Physiol. 2009, 219, 652–658. [CrossRef] [PubMed]

22. Parnell, E.; Smith, B.O.; Yarwood, S.J. The cAMP sensors, EPAC1 and EPAC2, display distinct subcellular distributions despite sharing a common nuclear pore localisation signal. Cell Signal. 2015, 27, 989–996. [CrossRef] [PubMed]

23. Zhang, Y. I-TASSER: Fully automated protein structure prediction in CASP8. Proteins Struct. Funct. Bioinform. 2009, 77, 100–113. [CrossRef] [PubMed]

24. Yang, J.; Zhang, Y. I-TASSER server: New development for protein structure and function predictions. Nucleic Acids Res. 2015, 43, W174–W181. [CrossRef] [PubMed]

25. Rehmann, H.; Das, J.; Knipscheer, P.; Wittinghofer, A.; Bos, J.L. Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. Nature 2006, 439, 625–628. [CrossRef]

26. Rehmann, H.; Arias-Palomo, E.; Hadders, M.A.; Schwede, F.; Llorca, O.; Bos, J.L. Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B. Nature 2008, 455, 124–127. [CrossRef]

27. White, M.A.; Tsalkova, T.; Mei, F.C.; Cheng, X. Conformational States of Exchange Protein Directly Activated by cAMP (EPAC1) Revealed by Ensemble Modeling and Integrative Structural Biology. Cells 2020, 9, 35. [CrossRef]

28. Luchowska-Stańska, U.; Morgan, D.; Yarwood, S.J.; Barker, G. Selective small-molecule EPAC activators. Biochem. Soc. Trans. 2019, 47, 1415–1427. [CrossRef]

29. Courilleau, D.; Bissier, M.; Jullian, J.C.; Lucas, A.; Bouyssou, P.; Fischmeister, R.; Blondeau, J.P.; Lezoualc’h, F. Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J. Biol. Chem. 2012, 287, 44192–44202. [CrossRef]

30. Schwede, F.; Bertinetti, D.; Langerijs, C.N.; Hadders, M.A.; Wienk, H.; Ellenbroek, J.H.; de Koning, E.J.P.; Rehmann, H.; Herberg, F.W.; Genieser, H.-G.; et al. Structure-Guided Design of Selective Epac1 and Epac2 Agonists. PLoS Biol. 2015, 13, e1002038. [CrossRef]

31. Vliem, M.J.; Ponsioen, B.; Schwede, F.; Pannekoek, W.J.; Riedl, J.; Kooistra, M.R.H.; Jalink, K.; Genieser, H.G.; Bos, J.L.; Rehmann, H. 8-pCPT-2’-O-Me-cAMP-AM: An improved Epac-selective cAMP analogue. ChemBioChem 2008, 9, 2052–2054. [CrossRef] [PubMed]

32. Parnell, E.; McElroy, S.P.; Wiejak, J.; Baillie, G.L.; Porter, A.; Adams, D.R.; Rehmann, H.; Smith, B.O.; Yarwood, S.J. Identification of a novel, small molecule partial agonist for the cyclic AMP sensor, EPAC1. Sci. Rep. 2017, 7, 1–12. [CrossRef] [PubMed]

33. Wiejak, J.; van Basten, B.; Luchowska-Stańska, U.; Hamilton, G.; Yarwood, S.J. The novel exchange protein activated by cyclic AMP 1 (EPAC1) agonist, I942, regulates inflammatory gene expression in human umbilical vascular endothelial cells (HUVECs). Biochim. Biophys. Acta Mol. Cell Res. 2019, 1866, 264–276. [CrossRef]

34. Shao, H.; Mohamed, H.; Boulton, S.; Huang, J.; Wang, P.; Chen, H.; Zhou, J.; Luchowska-Stańska, U.; Jentsch, N.G.; Armstrong, A.L.; et al. Mechanism of Action of an EPAC1-Selective Competitive Partial Agonist. J. Med. Chem. 2020. [CrossRef] [PubMed]

35. Wang, P.; Luchowska-Stańska, U.; van Basten, B.; Chen, H.; Liu, Z.; Wiejak, J.; Whelan, P.; Morgan, D.; Lochhead, E.; Barker, G.; et al. Synthesis and Biochemical Evaluation of Non-Cyclic Nucleotide Exchange Protein Directly Activated by cAMP 1 (EPAC1) Regulators. J. Med. Chem. 2020. [CrossRef]

36. Beck, E.M.; Parnell, E.; Cowley, A.; Porter, A.; Gillespie, J.; Robinson, J.; Robinson, L.; Pannifer, A.D.; Hamon, V.; Jones, P.; et al. Identification of A Novel Class of Benzofuran Oxoacetic Acid-Derived Ligands that Selectively Activate Cellular EPAC1. Cells 2019, 8, 1425. [CrossRef]

37. Chen, H.; Tsalkova, T.; Mei, F.C.; Hu, Y.; Cheng, X.; Zhou, J. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg. Med. Chem. Lett. 2012, 22, 4038–4043. [CrossRef]
38. Tsalkova, T.; Mei, F.C.; Cheng, X. A fluorescence-based high-throughput assay for the discovery of exchange protein directly activated by cyclic AMP (EPAC) antagonists. *PLoS ONE* **2012**, *7*, e30441. [CrossRef]

39. Almahariq, M.; Tsalkova, T.; Mei, F.C.; Chen, H.; Zhou, J.; Sastry, S.K.; Schwede, F.; Cheng, X. A Novel EPAC-Specific Inhibitor Suppresses Pancreatic Cancer Cell Migration and Invasions. *Mol. Pharmacol.* **2013**, *83*, 122–128. [CrossRef]

40. Gong, B.; Shelite, T.; Mei, F.C.; Ha, T.; Hu, Y.; Xu, G.; Chang, Q.; Wakamiya, M.; Ksiazek, T.G.; Boor, P.J.; et al. Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 19615–19620. [CrossRef]

41. Rehmann, H. Epac-Inhibitors: Facts and Artefacts. *Sci. Rep.* **2013**, *3*. [CrossRef] [PubMed]

42. Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F.C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N′-phenyl-acetohydrazonoyl Cyane Analogue: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. *J. Med. Chem.* **2015**, *58*, 6033–6047. [CrossRef] [PubMed]

43. Brown, L.M.; Rogers, K.E.; Aroonsakool, N.; McCammon, J.A.; Insel, P.A. Allosteric Inhibition of Epac computational modeling and experimental validation to identify allosteric sites and inhibitors. *J. Biol. Chem.* **2014**, *289*, 29148–29157. [CrossRef] [PubMed]

44. Courilleau, D.; Bouyssou, P.; Fischmeister, R.; Lezoualc’h, F.; Blondeau, J.P. The (R)-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1). *Biochem. Biophys. Res. Commun.* **2013**, *440*, 443–448. [CrossRef] [PubMed]

45. Boulton, S.; Selvaratnam, R.; Blondeau, J.P.; Lezoualc’h, F.; Melacini, G. Mechanism of Selective Enzyme Inhibition through Uncompetitive Regulation of An allosteric Agonist. *J. Am. Chem. Soc.* **2018**, *140*, 9624–9637. [CrossRef] [PubMed]

46. Ahmed, A.; Boulton, S.; Shao, H.; Akimoto, M.; Natarajan, A.; Cheng, X.; Melacini, G. Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective. *Cells* **2019**, *8*, 1462. [CrossRef]

47. Laudette, M.; Zuo, H.; 1, F.L.; Schmidt, M. Epac Function and cAMP Scaffolds in the Heart and Lung. *J. Cardiovasc. Dev. Dis.* **2018**, *5*, 9. [CrossRef]

48. Laudette, M.; Coluccia, A.; Sainte-Marie, Y.; Solari, A.; Fazal, P.; Silvestri, R.; Mialet-Perez, J.; Pons, S.; Ghaleb, B.; et al. Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. *Cardiovasc. Res.* **2019**, *115*, 1766–1777. [CrossRef]

49. Bufano, M.; Laudette, M.; Blondeau, J.P.; Lezoualc’h, F.; Nalli, M.; Silvestri, R.; Brancale, A.; Coluccia, A. Modeling Epac1 interactions with the allosteric inhibitor AM-001 by co-solvent molecular dynamics. *J. Comput. Aided. Mol. Des.* **2020**. [CrossRef]

50. Ali, D.C.; Naveed, M.; Gordon, A.; Majeed, F.; Saeed, M.; Ogbuke, M.I.; Atif, M.; Zubair, H.M.; Changxing, L. β-Adrenergic receptor, an essential target in cardiovascular diseases. *Heart Fail. Rev.* **2019**, *25*, 343–354. [CrossRef]

51. De Lucia, C.; Eguchi, A.; Koch, W.J. New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging. *Front. Pharmacol.* **2018**. [CrossRef] [PubMed]

52. Balligand, J.-L. Cardiac salvage by tweaking with β3-adrenergic receptors. *Cardiovasc. Res.* **2016**, *111*, 1286133. [CrossRef] [PubMed]

53. De Lucia, C.; Femminella, G.D.; Gambino, G.; Pagano, G.; Allocca, E.; Rengo, G.; Silvestri, C.; Leosco, D.; Ferrara, N.; Rengo, G. Adrenal adrenoceptors in heart failure. *Front. Physiol.* **2014**, *5*. [CrossRef] [PubMed]

54. Berthouze-Duquesnes, M.; Lucas, A.; Saulière, A.; Sin, Y.Y.; Laurent, A.-C.; Galès, C.; Baillie, G.; Lezoualc’h, F. Specific interactions between Epac1, β-arrestin2 and PDE4D5 regulate β-adrenergic receptor subtype differential effects on cardiac hypertro-phy signaling. *Cell Signal.* **2013**, *25*, 970–980. [CrossRef]

55. Laurent, A.-C.; Bissier, M.; Lucas, A.; Tortosa, F.; Roumieux, M.; de régibus, A.; Swiader, A.; Sainte-Marie, C.; Heymes, Y.; Vindis, C.; et al. Exchange Protein Directly Activated by cAMP 1 Promotes Autophagy During Cardiomyocyte Hypertrophy. 2015. Available online: https://pubmed.ncbi.nlm.nih.gov/25411381/?from_term=laurent+epac+hypertrophy&from_pos=1 (accessed on 17 April 2020).

56. Métrich, M.; Lucas, A.; Gustinah, M.; Samuel, J.-L.; Heymes, C.; Morel, E.; Lezoualc’h, F. Epac mediates β-adrenergic receptor-induced cardiomyocyte hypertrophy. *Circ. Res.* **2008**, *102*, 959–965. [CrossRef]

57. Mangmool, S.; Shukla, A.; Rockman, H. B-Arrestin-dependent activation of Ca2+/calmodulin kinase II after B1–adrenergic receptor stimulation. *J. Cell Biol.* **2010**. [CrossRef]
58. Métrich, M.; Berthouze, M.; Morel, E.; Crozatier, B.; Gomez, A.M.; Lezoualc’h, F. Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology. *Pflugers Arch. Eur. J. Physiol.* 2010, 459, 535–546. [CrossRef]

59. Pereira, L.; Ruiz-Hurtado, G.; Morel, E.; Laurent, A.-C.; Métrich, M.; Domínguez, A.; Lauton, S.; Lucas, A.; Benítez, J.-P.; Bers, D.M.; et al. Epac enhances excitation-transcription coupling in cardiac myocytes. *J. Mol. Cell. Cardiol.* 2012, 52, 283–291. [CrossRef]

60. Oestreich, E.A.; Malik, S.; Goonasekera, S.A.; Blaxall, B.C.; Kelley, G.G.; Dirksen, R.T.; Smrcka, A.V. Epac and phospholipase Cε regulate Ca2+ release in the heart by activation of protein kinase Cε and calcium-calmodulin kinase II. *J. Biol. Chem.* 2009, 284, 1514–1522. [CrossRef]

61. Oestreich, E.A.; Wang, H.; Malik, S.; Kaproth-Joslin, K.A.; Blaxall, B.C.; Kelley, G.G.; Dirksen, R.T.; Smrcka, A.V. Epac-mediated activation of phospholipase Cε plays a critical role in β-adrenergic receptor-dependent enhancement of Ca2+ mobilization in cardiac myocytes. *J. Biol. Chem.* 2007, 282, 5488–5495. [CrossRef]

62. Morel, E.; Marcantoni, A.; Gastineau, M.; Birkedal, R.; Rochais, F.; Garnier, A.; Lompré, A.M.; Vandecasteele, G.; Lezoualc’h, F. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. *Circ. Res.* 2005, 97, 1296–1304. [CrossRef] [PubMed]

63. Métrich, M.; Laurent, A.C.; Breckler, M.; Duquesnes, N.; Hmitou, I.; Courillau, D.; Blondeau, J.P.; Crozatier, B.; Lezoualc’h, F.; Morel, E. Epac activation induces histone deacetylase nuclear export via a Ras-dependent signalling pathway. *Cell Signal.* 2010, 22, 1459–1468. [CrossRef] [PubMed]

64. Freichel, M.; Berlin, M.; Schünger, A.; Mathur, I.; Bameister, L.; Medert, R.; Frede, W.; Marx, A.; Seguin, S.; Londoño, J.E.C. TRP Channels in the Heart. In *Neurobiol. Cell Signal.* 2019, pp. 149–185. [CrossRef]

65. Domínguez-Rodríguez, A.; Ruiz-Hurtado, G.; Sabourin, J.; Gómez, A.M.; Alvarez, J.L.; Benítez, J.P. Proarrhythmic effect of sustained EPAC activation on TRPC3/4 in rat ventricular cardiomyocytes. *J. Mol. Cell. Cardiol.* 2015, 87, 74–78. [CrossRef] [PubMed]

66. Aflaki, M.; Qi, X.-Y.; Xiao, L.; Ordog, B.; Tadevosyan, A.; Luo, X.; Maguy, A.; Shi, Y.; Tardif, J.-C.; Nattel, S. Exchange protein directly activated by cAMP mediates slow delayed-rectifier current remodeling by sustained β-adrenergic activation in guinea pig hearts. *Circ. Res.* 2014, 114, 993–1003. [CrossRef] [PubMed]

67. Clapham, K.R.; Singh, I.; Capuano, I.S.; Rajagopal, S.; Chun, H.J. MEF2 and the Right Ventricle: From Development to Disease. *Front. Cardiovasc. Med.* 2019, 6, 29. [CrossRef]

68. Sun, L.; Kondeti, V.K.; Xie, P.; Raparia, K.; Kanwar, Y.S. Epac1-Mediated, High Glucose-Induced Renal Proximal Tubular Cells Hypertrophy via the Akt/p21 Pathway. *Am. J. Pathol.* 2011, 179, 1706–1718. [CrossRef]

69. Mediero, A.; Perez-Aso, M.; Cronstein, B.N. Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements. *FASEB J.* 2014, 28, 4901–4913. [CrossRef]

70. Gloorich, M.; Vliem, M.J.; Prummel, E.; Meijer, L.A.T.; Rensen, M.G.A.; Rehmann, H.; Bos, J.L. The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity. *J. Cell Biol.* 2011, 193, 1009–1020. [CrossRef]

71. Liu, C.; Takahashi, M.; Li, Y.; Dillon, T.J.; Kaech, S.; Stork, P.J.S. The Interaction of Epac1 and Ran Promotes Rap1 Activation at the Nuclear Envelope. *Mol. Cell. Biol.* 2010, 30, 3956–3969. [CrossRef]

72. Baameur, F.; Singhmar, P.; Zhou, Y.; Hancock, J.F.; Cheng, X.; Heijnen, C.J.; Kavelaars, A. Epac1 interacts with importin 81 and controls neurite outgrowth independently of cAMP and Rap1 OPEN. *Nat. Publ. Gr.* 2016, 6, 1–11. [CrossRef]

73. Pereira, L.; Rehmann, H.; Lao, D.H.; Erickson, J.R.; Bossuyt, J.; Chen, J.; Bers, D.M. Novel Epac fluorescent ligand reveals distinct Epac1 vs. Epac2 distribution and function in cardiomyocytes. *Proc. Natl. Acad. Sci. USA* 2015, 112, 3991–3996. [CrossRef] [PubMed]

74. Dodge-Kafka, K.L.; Soughayer, J.; Pare, G.C.; Michel, J.J.C.; Langeberg, L.K.; Kaploff, M.S.; Scott, J.D. The protein kinase A anchoring protein mAKAP co-ordinates two integrated cAMP effector pathways. *Nature* 2005, 437, 574–578. [CrossRef] [PubMed]

75. Schmidt, M.; Evellin, S.; Weemink, P.A.O.; Dorp, F.V.; Rehmann, H.; Lomasney, J.W.; Jakobs, K.H. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. *Nat. Cell Biol.* 2001, 3, 1020–1024. [CrossRef] [PubMed]
Cells 2020, 9, 1545

76. Zhang, L.; Malik, S.; Kelley, G.G.; Kapiloff, M.S.; Smrcka, A.V. Phospholipase Cε scaffolds to muscle-specific A kinase anchoring protein (mAKAPβ) and integrates multiple hypertrophic stimuli in cardiac myocytes. J. Biol. Chem. 2011, 286, 23012–23021. [CrossRef]

77. Zhang, L.; Malik, S.; Pang, J.; Wang, H.; Park, K.M.; Yule, D.J.; Blaxall, B.C.; Smrcka, A.V. Phospholipase Cε Hydrolyzes Perinuclear Phosphatidylinositol 4-Phosphate to Regulate Cardiac Hypertrophy. Cell 2013, 153, 216–227. [CrossRef]

78. Jansen, S.R.; Poppinga, W.J.; de Jager, C.; Wieland, T.; Harms, T.; Schmidt, M. Epac1 links prostaglandin E2 to β-catenin-dependent transcription during epithelial-to-mesenchymal transition. Oncotarget 2016, 7, 46354. [CrossRef]

79. Huston, E.; Lynch, M.J.; Mohamed, A.; Collins, D.M.; Hill, E.V.; Macleod, R.; Krause, E.; Baillie, G.S.; Houslay, M.D. EPAC and PKA Allow cAMP Dual Control Over DNA-PK Nuclear Translocation. 2008. Available online: www.pnas.org/cgi/content/full/ (accessed on 30 April 2020).

80. Wang, Z.; Liu, D.; Varin, A.; Nicolas, V.; Courilleau, D.; Mateo, P.; Caubere, C.; Rouet, P.; Gomez, A.-M.; Vandecasteele, G.; et al. A cardiac mitochondrial cAMP signaling pathway regulates calcium accumulation, permeability transition and cell death. Cell Death Dis. 2016, 7. [CrossRef]

81. Fazal, L.; Laudette, M.; Paula-Gomes, S.; Pons, S.; Conte, C.; Tortosa, F.; Sicard, P.; Sainte-Marie, Y.; Bissierer, M.; Lairez, O.; et al. Multifunctional mitochondrial Epac1 controls myocardial cell death. Circ. Res. 2017, 120, 645–657. [CrossRef]

82. Wang, H.; Iii, W.G.R.; Wang, Z.; Mei, F.C.; Cai, M.; Du, G.; Chen, J.; Chen, Y. Inhibition of Epac1 suppresses mitochondrial fission and reduces neointima formation induced by vascular injury OPEN. Sci. Rep. 2016, 6, 36552. [CrossRef]

83. Del, D.P.; Amgalan, D.; Linkermann, A.; Liu, Q.; Kitsis, R.N. Regulated Cell Death and Implications for Heart Disease. Physiol. Rev. 2019, 99, 1765–1817. [CrossRef]

84. Mangmoel, S.; Hemplueska, P.; Parichatikanond, W.; Chattipakorn, N. Epac is Required for GLP-1R-Mediated Permeability Transition and Cell Death. J. Biol. Chem. 2017, 292, 13961–13969. [CrossRef] [PubMed]

85. Khaliullin, C.I.; Khaliullin, I.; Bond, M.; James, A.F.; Dyar, Z.; Amini, R.; Johnson, J.L.; Suleiman, M.-S. Functional and cardioprotective effects of simultaneous and individual activation of protein kinase A and Epac. Br. J. Pharmacol. 2017, 174, 438. [CrossRef] [PubMed]

86. Jayarajan, V.; Appukuttan, A.; Aslam, M.; Reusch, P.; Regitz-Zagrosek, V.; Ladiiov, Y. Regulation of AMPK activity by type 10 adenylyl cyclase: Contribution to the mitochondrial biology, cellular redox and energy homeostasis. Cell. Mol. Life Sci. 2019, 76, 1–15. [CrossRef] [PubMed]

87. Qin, Y.; Stokman, G.; Yan, K.; Ramaiyahgari, S.; Verbeek, F.; de Graauw, M.; van de Water, B.; Price, L.S. cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. Br. J. Pharmacol. 2011, 165, 1137–1150. [CrossRef]

88. Szanda, G.; Wisniewski, É.; Rajki, A.; Spáť, A. Mitochondrial cAMP exerts positive feedback on mitochondrial Ca2+ uptake via the recruitment of Epac1. J. Cell Sci. 2018, 131. [CrossRef]

89. Okumura, S.; Fujita, T.; Cai, W.; Jin, M.; Namekata, I.; Mototani, Y.; Jin, H.; Ohnuki, Y.; Tsuneoka, Y.; Kurotani, R.; et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J. Clin. Investig. 2014, 124. [CrossRef]

90. Suzuki, S.; Yoshikawa, U.; Abe, T.; Kiyonari, H.; Yamashita, N.; Kato, Y.; Kurotani, R.; Sato, M.; Okumura, S.; Ishikawa, Y. Differential Roles of Epac in Regulating Cell Death in Neuronal and Myocardial Cells. J. Biol. Chem. 2010, 285, 24248–24259. [CrossRef]

91. Kumar, N.; Gupta, S.; Dabral, S.; Singh, S.; Sehrawat, S. Role of exchange protein directly activated by cAMP (EPAC1) in breast cancer cell migration and apoptosis. Mol. Cell. Biochem. 2017, 1, 3. [CrossRef]

92. Moon, E.Y.; Lee, G.H.; Lee, M.S.; Kim, H.M.; Lee, J.W. Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways. Life Sci. 2012, 90, 373–380. [CrossRef]

93. Cho, E.A.; Juhnn, Y.S. The cAMP signaling system inhibits the repair of γ-ray-induced DNA damage by promoting Epac1-mediated proteasomal degradation of XRCC1 protein in human lung cancer cells. Biochem. Biophys. Res. Commun. 2012, 422, 256–262. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).